Operational updates
Pharming acquires exclusive license to CDZ173, a late stage drug for the treatment of APDS
Pharming Group N.V. announces it has entered into a development collaboration and license agreement with Novartis to develop and commercialize CDZ173, a small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor being developed by Novartis to treat patients with Activated Phosphoinositide 3-kinase Delta Syndrome (“APDS”).
''This transaction represents a great milestone for Pharming. The license of CDZ173 is our first step towards building off the commercial success of Ruconest in HAE to grow and diversify our portfolio.''
- Sijmen de Vries - CEO